Research and pilot analysis of <i>bevacizumab</i> repurposing potential and its impact in clinical practice-Reference-Cited by-同舟云学术

Research and pilot analysis of bevacizumab repurposing potential and its impact in clinical practice

Published:2024-06-22 Issue:1 Volume:38 Page:
ISSN:1310-2818
Container-title:Biotechnology & Biotechnological Equipment
language:en
Short-container-title:Biotechnology & Biotechnological Equipment

Author:

Ivanov Antonio¹^ORCID,Getova-Kolarova Violeta¹^ORCID,Belcheva Valentina²^ORCID,Grigorov Evgeni³^ORCID,Getov Ilko¹^ORCID

Affiliation:

1. Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria

2. Department of Pharmaceutical Sciences, Medical College, Trakia University-Stara Zagora, Stara Zagora, Bulgaria

3. Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University “Prof. Dr. Paraskev Stoyanov”-Varna, Varna, Bulgaria

Funder

European Union-NextGenerationEU

National Recovery and Resilience Plan of the Republic of Bulgaria

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13102818.2024.2357191

Reference34 articles.

1. CRISP_ Special Edition August 2021.pdf. Available from: https://tinyurl.com/yc5c5v9e

2. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

3. Drug Approval Package: Avastin (Bevacizum) NDA #125085. [Internet]. [cited 2024 Mar 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/STN-125085_Avastin.cfm

4. Avastin EPAR Scientific Discussion - 08/08/2007. [Internet]. [cited 2022 May 3]. Available from: https://www.ema.europa.eu/en/documents/scientific-discussion-variation/avastin-h-c-582-ii-0008-epar-scientific-discussion-variation_en.pdf

5. Avastin EPAR Scientific Discussion - 12/10/2007. [Internet]. [cited 2022 May 3]. Available from: https://www.ema.europa.eu/en/documents/scientific-discussion-variation/avastin-h-c-582-ii-0009-epar-scientific-discussion-variation_en.pdf